These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 11897607)
1. Cloning and expression of class A beta-lactamase gene blaA(BPS) in Burkholderia pseudomallei. Cheung TK; Ho PL; Woo PC; Yuen KY; Chau PY Antimicrob Agents Chemother; 2002 Apr; 46(4):1132-5. PubMed ID: 11897607 [TBL] [Abstract][Full Text] [Related]
2. Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Tribuddharat C; Moore RA; Baker P; Woods DE Antimicrob Agents Chemother; 2003 Jul; 47(7):2082-7. PubMed ID: 12821450 [TBL] [Abstract][Full Text] [Related]
3. Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification. Chirakul S; Somprasong N; Norris MH; Wuthiekanun V; Chantratita N; Tuanyok A; Schweizer HP Int J Antimicrob Agents; 2019 May; 53(5):582-588. PubMed ID: 30639528 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance. Chirakul S; Norris MH; Pagdepanichkit S; Somprasong N; Randall LB; Shirley JF; Borlee BR; Lomovskaya O; Tuanyok A; Schweizer HP Sci Rep; 2018 Jul; 8(1):10652. PubMed ID: 30006637 [TBL] [Abstract][Full Text] [Related]
5. Functional characterization of OXA-57, a class D beta-lactamase from Burkholderia pseudomallei. Keith KE; Oyston PC; Crossett B; Fairweather NF; Titball RW; Walsh TR; Brown KA Antimicrob Agents Chemother; 2005 Apr; 49(4):1639-41. PubMed ID: 15793160 [TBL] [Abstract][Full Text] [Related]
7. Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria. Somprasong N; Hall CM; Webb JR; Sahl JW; Wagner DM; Keim P; Currie BJ; Schweizer HP mBio; 2020 Apr; 11(2):. PubMed ID: 32291300 [No Abstract] [Full Text] [Related]
8. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems. Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233 [TBL] [Abstract][Full Text] [Related]
9. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. Sam IC; See KH; Puthucheary SD J Clin Microbiol; 2009 May; 47(5):1556-8. PubMed ID: 19297597 [TBL] [Abstract][Full Text] [Related]
10. Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. Niumsup P; Wuthiekanun V J Antimicrob Chemother; 2002 Oct; 50(4):445-55. PubMed ID: 12356787 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. Ho PL; Cheung TK; Yam WC; Yuen KY J Antimicrob Chemother; 2002 Nov; 50(5):723-6. PubMed ID: 12407130 [TBL] [Abstract][Full Text] [Related]
12. Expression of beta-lactamases in Yersinia enterocolitica strains of biovars 2, 4 and 5. Stock I; Heisig P; Wiedemann B J Med Microbiol; 1999 Nov; 48(11):1023-1027. PubMed ID: 10535647 [TBL] [Abstract][Full Text] [Related]
13. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. Sarovich DS; Price EP; Von Schulze AT; Cook JM; Mayo M; Watson LM; Richardson L; Seymour ML; Tuanyok A; Engelthaler DM; Pearson T; Peacock SJ; Currie BJ; Keim P; Wagner DM PLoS One; 2012; 7(2):e30789. PubMed ID: 22363490 [TBL] [Abstract][Full Text] [Related]
14. Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei. Randall LB; Dobos K; Papp-Wallace KM; Bonomo RA; Schweizer HP Antimicrob Agents Chemother; 2015 Dec; 60(3):1509-14. PubMed ID: 26711764 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of BAL30072 against Burkholderia pseudomallei. Mima T; Kvitko BH; Rholl DA; Page MG; Desarbre E; Schweizer HP Int J Antimicrob Agents; 2011 Aug; 38(2):157-9. PubMed ID: 21596528 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of beta-lactamases and their genes (blaA and blaB) in Yersinia intermedia and Y. frederiksenii. Mittal S; Mallik S; Sharma S; Virdi JS BMC Microbiol; 2007 Apr; 7():25. PubMed ID: 17407578 [TBL] [Abstract][Full Text] [Related]
18. Beta-lactamase expression in Yersinia enterocolitica biovars 1A, 1B, and 3. Stock I; Heisig P; Wiedemann B J Med Microbiol; 2000 May; 49(5):403-408. PubMed ID: 10798551 [TBL] [Abstract][Full Text] [Related]
19. Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase. Papp-Wallace KM; Becka SA; Taracila MA; Winkler ML; Gatta JA; Rholl DA; Schweizer HP; Bonomo RA Antimicrob Agents Chemother; 2016 Feb; 60(2):777-88. PubMed ID: 26596949 [TBL] [Abstract][Full Text] [Related]
20. Structural Variabilities in β-Lactamase (blaA) of Different Biovars of Yersinia enterocolitica: Implications for β-Lactam Antibiotic and β-Lactamase Inhibitor Susceptibilities. Singhal N; Srivastava A; Kumar M; Virdi JS PLoS One; 2014; 10(4):e0123564. PubMed ID: 25919756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]